

1 December 2020

Ms Jane Thorley  
Trading and Settlement Manager  
National Stock Exchange of Australia  
1 Bligh Street  
Sydney NSW 2000  
By email: jane.thorley@nsx.com.au

Dear Ms Thorley

**Request for trading halt: iQX Limited (NSX: IQX)**

iQX Limited (NSX: IQX) (**iQX** or the **Company**) requests an immediate trading halt be granted by the National Stock Exchange of Australia with respect to its securities. The trading halt is requested in relation to the following development:

Following announcement by the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Company is pleased to announce that the Wyss Institute's eRapid technology has been licensed to The iQ Group Global group of companies for COVID-19 diagnostic applications.

This announcement follows the research agreement between the Wyss Institute and Life Science Biosensor Diagnostics Pty Ltd (**LSBD**), in which the Company holds a 19% equity position, reached in May 2020.

As part of the Wyss Institute's collective response to the COVID-19 pandemic, the Wyss Institute team leveraged their eRapid technology to build an effective SARS-CoV-2 detection system to meet the long-term challenge of providing point-of-care diagnostics for use in physician's offices, pharmacies, or at home, which might be used to identify whether a patient is actively infected or if he or she has been infected or vaccinated in the past and has developed an active immune response.

"eRapid's features and capabilities would make it an effective tool for easily tracing active immunity in infected individuals and those that recovered from COVID-19 to help determine their basis for resistance. Such a versatile platform that helps us better understand how the disease develops, persists, and can be controlled could be an invaluable asset in the fight against the pandemic," said Wyss Institute Senior Staff Scientist Pawan Jolly, PhD, who helped lead this effort as part of the Wyss Institute's Bioinspired Therapeutics & Diagnostics Platform, where the eRapid technology was developed and de-risked in a high-priority Institute Project with industry-minded expertise in technology and business development.

"Non-invasive, low-cost and scalable SARS-Cov-2 antibody testing is urgently needed to estimate the incidence and prevalence of SARS-Cov-2 infection at the general population level. We intend to focus on placing this SARS-Cov 2-test as a potential companion diagnostic to the vaccination programs globally. Given the analytical characteristics of the biosensor and its stage of development, the combined technologies position us excellently to develop a more accurate, sensitive, and real-time SARS-CoV-2 test

for diagnostic, point-of-care testing and pre-vaccination screening to meet this urgent global need,” said Dr George Syrmalis, Group CEO of The iQ Group Global group of companies.

Below is the hyperlink to the Harvard University announcement:

[https://wyss.harvard.edu/news/harvards-wyss-institute-licenses-its-erapid-technology-to-the-iq-group-global-to-accelerate-the-development-of-covid-19-diagnostic-capabilities/?utm\\_medium=email&\\_hsmt=101339064&\\_hsenc=p2ANqtz-82iJVuxxv59pt7uH9h9p8mWGqIFJLd7hNxZKjKAibTGICRMg6-ZG8H2N6bJZRx499T6JfR57jfe0U67a-yLFAeh31uk1LYX5gDfOKFNpBJxBkJ91s&utm\\_content=101339064&utm\\_source=hs\\_email](https://wyss.harvard.edu/news/harvards-wyss-institute-licenses-its-erapid-technology-to-the-iq-group-global-to-accelerate-the-development-of-covid-19-diagnostic-capabilities/?utm_medium=email&_hsmt=101339064&_hsenc=p2ANqtz-82iJVuxxv59pt7uH9h9p8mWGqIFJLd7hNxZKjKAibTGICRMg6-ZG8H2N6bJZRx499T6JfR57jfe0U67a-yLFAeh31uk1LYX5gDfOKFNpBJxBkJ91s&utm_content=101339064&utm_source=hs_email)

1. **Reason for trading halt** – to avoid trading taking place until the market has an opportunity to comprehend the development.

2. **Duration of the trading halt** – iQX expects the trading halt will last from the release of this announcement until the commencement of trading on Wednesday, 2 December 2020.

iQX is not aware of any reason why the trading halt should not be granted.

Yours sincerely

A handwritten signature in black ink, appearing to read 'George Syrmalis', written over a horizontal line.

**Dr George Syrmalis**  
**Chairman and CEO**